A kind of preparation method of Mirabegron

An intermediate and reaction technology, applied in the field of preparation of Mirabegron, can solve problems such as difficulty in realizing industrial production, difficulty in obtaining starting materials, long synthetic route, etc., and achieve fewer steps in the synthetic route, broad prospects and industrial application Good effect of value, purity

Active Publication Date: 2022-04-22
ANHUI QINGYUN PHARMA & CHEM
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] This route is a new route, but it is difficult to realize industrial production because the oxidation of this route uses highly polluting potassium permanganate and the starting materials are not easy to obtain.
[0013] From the above review, it can be known that the synthesis of mirabegron is difficult to realize industrial production because the synthesis route is too long and the yield is low, or because the cost of expensive reagents is high, or the starting materials that are difficult to obtain are used. Therefore, the development of raw materials The synthesis route of mirabegron with cheap and easy to obtain, few reaction steps and low cost has broad prospects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of preparation method of Mirabegron
  • A kind of preparation method of Mirabegron
  • A kind of preparation method of Mirabegron

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Synthesis of S1, intermediate (R)-2-hydroxyl-N-(4-nitrophenethyl)-2-phenylacetamide

[0043] Add 273g (1.64mol, 1.0eq) of p-nitrophenylethylamine, (R)-mandelic acid 250g (1.64mol, 1.0eq) and 1500mL of xylene (mandelic acid V / m is 6), under the protection of nitrogen, the temperature is raised to 140 ° C for reflux, and the reaction is kept for 7 hours. The progress of the reaction is monitored by HPLC. Dissolve methane, wash with 500mL*2 of 5% dilute hydrochloric acid and 500mL*2 of 5% sodium hydroxide respectively, dry the organic phase over anhydrous sodium sulfate, remove dichloromethane under reduced pressure, and obtain the product after drying (R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide is about 429 g, the yield is 87.2%, and the purity is 99.2%.

[0044] Synthesis of S2, intermediate (R)-2-((4-nitrophenethyl)amino)-1-phenylethanol hydrochloride

[0045]Add 400g (1.33mol, 1.0eq) of the intermediate (R)-2-hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide, ...

Embodiment 2

[0051] Synthesis of S1, intermediate (R)-2-hydroxyl-N-(4-nitrophenethyl)-2-phenylacetamide

[0052] Add 273g (1.64mol, 1.0eq) of p-nitrophenylethylamine, (R)-mandelic acid 499g (3.28mol, 2.0eq) and 1750mL of xylene (mandelic acid V / m is 3.5), under the protection of nitrogen, the temperature is raised to 160°C and refluxed, and the reaction is kept for 10 hours. The progress of the reaction is monitored by HPLC. Dissolve methane, wash with 500mL*2 of 5% dilute hydrochloric acid and 500mL*2 of 5% sodium hydroxide respectively, dry the organic phase over anhydrous sodium sulfate, remove dichloromethane under reduced pressure, and obtain the product after drying (R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide is about 450 g, the yield is 91.5%, and the purity is 99.3%.

[0053] Synthesis of S2, intermediate (R)-2-((4-nitrophenethyl)amino)-1-phenylethanol hydrochloride

[0054] Add 400g (1.33mol, 1.0eq) of the intermediate (R)-2-hydroxy-N-(4-nitrophenethyl)-2-phenylacetami...

Embodiment 3

[0060] Synthesis of S1, intermediate (R)-2-hydroxyl-N-(4-nitrophenethyl)-2-phenylacetamide

[0061] Add 273g (1.64mol, 1.0eq) of p-nitrophenylethylamine, (R)-mandelic acid 375g (2.46mol, 1.5eq) and 1875mL of dimethylbenzene (mandelic acid V / m is 5), under the protection of nitrogen, the temperature is raised to 150 ° C and refluxed, and the reaction is kept for 9 hours. The progress of the reaction is monitored by HPLC. Dissolve methane, wash with 500mL*2 of 5% dilute hydrochloric acid and 500mL*2 of 5% sodium hydroxide respectively, dry the organic phase over anhydrous sodium sulfate, remove dichloromethane under reduced pressure, and obtain the product after drying (R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide is about 454 g, the yield is 92.3%, and the purity is 99.2%.

[0062] Synthesis of S2, intermediate (R)-2-((4-nitrophenethyl)amino)-1-phenylethanol hydrochloride

[0063] Add 400g (1.33mol, 1.0eq) of the intermediate (R)-2-hydroxy-N-(4-nitrophenethyl)-2-pheny...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method of mirabegron, which relates to the technical field of medicine preparation, comprising the following steps: R-mandelic acid and p-nitrophenylethylamine undergo amide condensation reaction at high temperature to obtain intermediate (R)- 2‑Hydroxy‑N‑(4‑nitrophenethyl)‑2‑phenylacetamide; then the amide carbonyl is reduced by diisobutylaluminum hydride to obtain the intermediate (R)‑2‑((4‑nitro Phenylethyl)amino)-1-phenylethanol hydrochloride; then the nitro group is reduced by the ammonium formate-Pd / C reduction system to obtain the intermediate (R)-2-((4-aminophenylethyl)amino) ‑1‑phenylethanol; final condensation reaction with aminothiazoleacetic acid to obtain mirabegron. The mirabegron prepared by the present invention has good purity, high yield, few synthetic circuit steps, mild and controllable conditions, simple and convenient operation, low cost and is suitable for industrial production, and has broad prospects and industrial application value.

Description

technical field [0001] The invention relates to the technical field of medicine preparation, in particular to a preparation method of mirabegron. Background technique [0002] Mirabegron was developed by Japan's Astellas Pharmaceutical Company (Astellas), and Yamanouchi Pharmaceutical Co., Ltd. applied for the compound patent of Mirabegron in Japan on October 17, 1997, and protected its preparation method. At present, it has applied for patent protection in many countries and regions such as the United States, Europe, and China. On September 16, 2011, Mirabegron was launched for sale in Japan. In June 2012, it was approved by the US FDA for listing in the United States. As the first orally effective β3 adrenergic receptor agonist drug for the treatment of overactive bladder, the successful marketing of Mirabegron has filled the gap in the treatment of overactive bladder with β adrenergic receptor agonists. [0003] The currently disclosed synthetic routes mainly include the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D277/40
CPCC07D277/40
Inventor 黄欢黄庆国李凯施亚琴
Owner ANHUI QINGYUN PHARMA & CHEM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap